Clinical Trial Update: A Study of Bomedemstat (MK-3543) in Participants With Mild or Moderate Hepatic Impairment (MK-3543-023) [Phase 1]

View source ↗

Summary

A Phase 1 study assessing the pharmacokinetics of Bomedemstat (MK-3543) in participants with mild or moderate hepatic impairment has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Insufficiency

Drugs mentioned

• Bomedemstat (bomedemstat)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatic Insufficiency | Phase 1 | Status: COMPLETED